Page 6 of 10
PD-L1 highly positive participants:
The results were available for 70 participants in the feladilimab + pembrolizumab group and
69 participants in the placebo + pembrolizumab group.
How long did the treatment delay the growth or return of the cancer?
Progression free survival (PFS) is measured from the time of randomisation to treatment
until the cancer grows or returns or the participant dies. The median PFS was calculated in
weeks for each treatment group at the data cut-off.
The results were available for 157 participants in the feladilimab + pembrolizumab group
and 156 participants in the placebo + pembrolizumab group.